ALX ONCOLOGY HOLDINGS INC

$12.98 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About ALX ONCOLOGY HOLDINGS INC

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. It is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), head and neck squamous cell carcinomas (HNSCC), gastric and breast cancer. Its preclinical program is focused on developing ALTA-002, which combines its signal regulatory protein alpha (SIRPa) and toll-like receptor 9 agonist antibody conjugate (TRAAC).

Stock Analysis

last close $12.98
1-mo return 40.2%
3-mo return 51.3%
avg daily vol. 238.53T
52-week high 81.19
52-week low 5.82
market cap. $467M
forward pe -
annual div. -
roe -24.6%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 88.5%
baraka

Subscribe now for daily local and international financial news

Subscribe